While PD-L1 expression is the most studied, emerging biomarkers such as tumor mutational burden, DNA damage repair alterations, tumor infiltration by CD8 T-cells, microsatellite instability-high status [65], the microbiome within digestive tracts [66, 67], localized tumor tissues [68], and blood [69] are gaining attention. This evidence concerns the gene CD8A and neoplasm.